The effect of tandospirone, a serotonin1A agonist, on memory function in schizophrenia

Background: The purpose of this study was to test the hypothesis that the addition of tandospirone, a 5-HT1A partial agonist, to ongoing treatment with typical antipsychotic drugs, would improve memory function in patients with schizophrenia. Methods: Eleven outpatients (male/female = 7/4) with schizophrenia who had been on stable doses of haloperidol and biperiden were given tandospirone, 30 mg/day, for 4 weeks. The Wechsler Memory Scale-Revised (WMS-R) was administered at baseline and 4 weeks after the addition of tandospirone. The Brief Psychiatric Rating Scale (BPRS; Total, Positive, and Negative subscale scores) and the Simpson-Angus Scale for the Extrapyramidal Symptoms (SAS) were also completed on the two occasions. To exclude the possibility of a practice effect on the WMS-R test, 11 age-matched patients with schizophrenia (M/F = 7/4) were reared at baseline and after a a 4-week interval. Results: Repeated measures analysis of variance revealed a significant time by group (patients with or without tandospirone) effect for the Verbal-, but not the Visual Memory composite scores of the WMS-R test; no significant change was observed in patients without tandospirone, whereas improvement in the Verbal Memory score was noted in patients receiving tandospirone. Moreover, there was improvement in the Inclusion score, an index of memory organization as measured by the Logical Memory subtest of WMS-R, only in patients with tandospirone. Scores on the BPRS and SAS weta improved during treatment with tandospirone, but the effects did not reach statistical significance. Conclusions: The results suggest that adjunctive treatment with 5-HT1A agonists may improve some types of memory function in schizophrenia. (C) 2001 Society of Biological Psychiatry.